Clinical Trial Detail

NCT ID NCT03287050
Title Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

transitional cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.